| 28939558 |
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Namchuk, M,
Germann, UA,
Roix, JJ,
Shapiro, P,
Hoover, RR,
Meshaw, K,
Fitzgibbon, M,
Emery, CM,
Samadani, R,
Furey, BF,
Markland, W,
Aronov, AM,
Saha, S,
Martinez-Botella, G,
DeCrescenzo, G,
Sorrell, DA,
Wick, MJ,
Hale, M,
Groover, A,
Welsch, DJ,
Boucher, DM
|
Mol. Cancer Ther. |
2017 |
| 27227380 |
Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
Ren, L,
Yin, J,
Wang, W,
Robarge, K,
Liu, L,
Moffat, J,
Chan, J,
Moreno, D,
Chou, KJ,
Chen, H,
Merchant, M,
Gaudino, JJ,
Stults, J,
Blake, JF,
Grina, J,
Gould, SE,
Martinson, M,
Qin, A,
Belvin, M,
Sullivan, F,
Mueller, L,
Schwarz, JB,
Zhou, A,
Burkard, M,
Rasor, K,
Dudley, DA,
Diaz, D,
Orr, C,
Pacheco, P,
Hunsaker, T,
Shahidi-Latham, S
|
J. Med. Chem. |
2016 |
